Dulaglutide label and trial reference

Start with Trulicity

Trulicity contains dulaglutide. Its US label describes a ready-to-use single-dose pen for once-weekly subcutaneous injection. It has type 2 diabetes and specified cardiovascular indications. It has no FDA weight-management indication as of November 6, 2026.

A label-supported weekly cadence does not tell a person which amount is appropriate. The prescriber determines the plan for the product and indication.

What REWIND measured

REWIND randomized 9,901 adults aged 50 or older with type 2 diabetes and either prior cardiovascular disease or risk factors. Participants received weekly dulaglutide or placebo in addition to existing care. Median follow-up was 5.4 years.

The primary outcome combined cardiovascular death, nonfatal heart attack, and nonfatal stroke. It occurred in 12.0% with dulaglutide versus 13.4% with placebo. A composite result describes the combined outcome; it does not establish a separate benefit for every component. All-cause mortality did not differ significantly. Gastrointestinal adverse events were more common with dulaglutide.

These findings apply to the studied diabetes population. They do not establish a cardiovascular prevention plan for a person without diabetes or an obesity indication.

Record the plan and its purpose

Keep the product name, pen strength, prescribed amount and unit, indication, weekly day, and actual administration dates. Include the clinician's instructions for an interruption or missed dose and the next review date.

Record symptoms and the glucose measurements the clinician requests. Keep other medicines in the same history, especially insulin or medicines that can cause low glucose. A weight change can be useful context, but the record should preserve the treatment's intended purpose. A tracker cannot select a different amount from the REWIND result.